HIMS stock monster insider trading alert

Core Viewpoint - Hims & Hers Health CEO Andrew Dudum sold a significant block of shares, marking the largest insider transaction since the company went public, raising approximately $33.4 million from the sale of 660,000 shares at an average price of $50.58 [1][4][5] Insider Trading Details - The sale was conducted outside of Dudum's pre-established trading plan and was made through a family trust [3] - Despite the sale, Dudum remains the largest individual shareholder with about 8 million shares held indirectly through various trusts, valued at approximately $388 million [4][5] Purpose of Sale - The company stated that the sale was for "tax and philanthropic purposes" and that Dudum continues to hold his full personal stake, emphasizing his commitment to the company's long-term growth [5] Market Performance - Hims & Hers has seen its stock price double over the past year, although it experienced a decline of over 4% on the day of the report and more than 13% for the week [8][10] - The company reported adjusted earnings of $0.17 per share for Q2 2025, exceeding estimates, while revenue rose 73% year-over-year to $544.8 million, though it fell short of analyst projections [10][11] Future Projections - For the third quarter, Hims & Hers projects revenue between $570 million and $590 million, aligning with analyst expectations of $583 million [11]